A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
News|Articles|December 8, 2015
Role of the Pharmacist in ACS Management with Platelet Aggregation Inhibitors
Andrew North, PharmD, BCPS, a specialty practice pharmacist in emergency medicine at the Ohio State University Wexner Medical Center, discusses the pharmacist's role in acute coronary syndrome management with platelet aggregation inhibitors.
Advertisement
Andrew North, PharmD, BCPS, a specialty practice pharmacist in emergency medicine at the Ohio State University Wexner Medical Center, discusses the pharmacist’s role in acute coronary syndrome management with platelet aggregation inhibitors.
This video was recorded at the 2015 American Society of Health-System Pharmacists Midyear Meeting.
Advertisement
Related to this article
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg vs placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5